PREECLAMPSIA AND LONG-TERM CARDIOVASCULAR FUNCTION -A SYSTEMATIC REVIEW AND META-ANALYSIS
Background: The current understanding of preeclampsia is that it is a placental mediated disease that resolves with delivery. However, there is increasing evidence to suggest that preeclampsia is associated with significant long term cardiovascular sequelae. Whilst the American Heart Association now recognises preeclampsia as a risk factor for cardiovascular disease, it is unclear whether these women require ongoing cardiovascular assessment after pregnancy. The aim of this systematic review is to examine cardiovascular function in women with a history of preeclampsia. With this review, we aim to inform clinicians of the role of routine postpartum cardiovascular assessment in preeclamptic women.
Methods: We performed a comprehensive search of electronic databases (MEDLINE, EMBASE, CINAHL and Cochrane) from inception to October 2018. Eligible studies included pregnant women with a history of preeclampsia who had cardiovascular assessment with echocardiography. Studies that assessed women with pre-existing cardiovascular disease were excluded. Variables assessed include blood pressure, mean arterial pressure, assessment of systolic and diastolic function, and left ventricular geometry to assess cardiac remodelling.
Results and Conclusions: The results of this systematic review are currently in progress and will be available for the Perinatal Society of Australia & New Zealand Annual Congress. Neither meets their full nutritional needs, therefore human milk fortifier (HMF) and occasionally other additives are added. As little as 0.8 g of HMF or 0.2 g of an additive may be required to be measured out. It was recognized that inconsistent and potentially inaccurate methods were being used to measure out HMF and additives. We therefore wanted to improve precision and develop a standardized procedure for measuring HMF and additives.
IMPROVING PRECISION WHEN MEASURING BREAST MILK FORTIFIERS AND BREAST MILK ADDITIVES
Methods: The current method of measuring HMF and additives at MHW was tested against 2 alternate methods:
1 -Metric measuring spoons tested and assumed to measure a set weight.
2 -Scales measuring as low as 0.02 g.
Results:
The syringe method showed an inaccuracy of up to 19%, the spoon method up to 10% and weighing on scales the lowest inaccuracy of up to 2.5%. The reference points where 0.2 g, 0.8 g and 1 g.
Conclusion: Medical scales are now used to measure HMF and additives at MHW, and a procedure has been developed. The higher precision in measurements could have significant accumulative effects on growth outcomes of this vulnerable patient group. This method has been found to be safe and user friendly and could easily be adopted by other neonatal units.
